Why Upstream Bio, Inc.’s (UPB) Stock Is Up 5.19%
As of Wednesday, September 02, Upstream Bio, Inc.’s UPB share price has surged by 5.19%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Upstream Bio, Inc.’s (UPB) Stock Is Down 5.88%
As of Monday, August 24, Upstream Bio, Inc.’s UPB share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Michael Rose
Why Upstream Bio, Inc.’s (UPB) Stock Is Up 9.71%
As of Friday, August 21, Upstream Bio, Inc.’s UPB share price has surged by 9.71%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Upstream Bio, Inc.’s (UPB) Stock Is Up 5.40%
As of Wednesday, August 19, Upstream Bio, Inc.’s UPB share price has surged by 5.40%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is Upstream Bio, Inc. (UPB) Overvalued?
We dive into why Upstream Bio, Inc. (UPB) could be considered overvalued on 2026-08-17, based on AAII’s Value Score and Grade.Jenna Brashear
Financial Summary
| Share Statistics | UPB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $354.4 | $288.9 | 33% |
|
| Shares Out (Mil) | 54.6 | 54.0 | 50% |
|
| Institutional Ownership | 99.9% | 93.1% | 96% |
|
| Float (Mil) | 42.8 | 41.4 | 44% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 522 | 480 | 60% |
|
| Price Change (52-week) |
(68.1%) | 59.9% | 10% |
|
| Growth | UPB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 7 | |
| Current EPS | ($0.727) | ($2.902) | ($2.931) | |
| Month Ago EPS | ($0.698) | ($2.841) | ($2.888) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.710) | ($2.904) | ($3.028) | |
| Year/Year Chg | (0.1%) | 8.9% | 19.1% | |
| Financials | UPB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $37 | 4% |
|
| Net Income (TTM) (Mil) | ($157) | ($43) | 8% |
|
| EPS (TTM) | ($2.886) | ($1.500) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($136) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $34 | $2 | 66% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $118 | $190 | 22% |
|
| Valuation | UPB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.31 | 2.84 | 33% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | UPB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (44.6%) | (47.7%) | 13% |
|
| ROE | (46.0%) | (55.0%) | 16% |
|
| Liabilities to Assets | 3.6% | 29.6% | 2% |
|
| F-Score | 4 | 3 | 33% |
|
Upstream Bio, Inc. did not pass any screens on 9/2/2026.
